ID   786-O
AC   CVCL_1051
SY   786-o; 786O; 786-0; 786.O; 786-O RCC; RCC 786-O; RCC_7860; RCC 7860; 7860; 786-0WT
DR   BTO; BTO:0003781
DR   CLO; CLO_0001486
DR   EFO; EFO_0005707
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-1932
DR   BCRC; 60243
DR   BioSample; SAMN03471906
DR   BioSample; SAMN10988199
DR   CCLE; 786O_KIDNEY
DR   CCRID; 3111C0001CCC000243
DR   CCRID; 3131C0001000700003
DR   CCRID; 3131C0001000700186
DR   CCRID; 3142C0001000001716
DR   CCRID; 3153C0001000000218
DR   CCTCC; GDC0159
DR   Cell_Model_Passport; SIDM00125
DR   ChEMBL-Cells; CHEMBL3308018
DR   ChEMBL-Targets; CHEMBL613102
DR   CLS; 300107/p747_786-O
DR   Cosmic; 687936
DR   Cosmic; 875874
DR   Cosmic; 897461
DR   Cosmic; 905947
DR   Cosmic; 972929
DR   Cosmic; 974305
DR   Cosmic; 982276
DR   Cosmic; 1044259
DR   Cosmic; 1092589
DR   Cosmic; 1175848
DR   Cosmic; 1305372
DR   Cosmic; 1312360
DR   Cosmic; 1481416
DR   Cosmic; 1998431
DR   Cosmic; 2036676
DR   Cosmic; 2520637
DR   Cosmic; 2663796
DR   Cosmic-CLP; 905947
DR   DepMap; ACH-000649
DR   ENCODE; ENCBS261AAA
DR   ENCODE; ENCBS413VCR
DR   ENCODE; ENCBS807WMR
DR   GDSC; 905947
DR   GEO; GSM2128
DR   GEO; GSM50226
DR   GEO; GSM50290
DR   GEO; GSM482711
DR   GEO; GSM743488
DR   GEO; GSM750838
DR   GEO; GSM799371
DR   GEO; GSM799377
DR   GEO; GSM799434
DR   GEO; GSM843437
DR   GEO; GSM846283
DR   GEO; GSM886845
DR   GEO; GSM887909
DR   GEO; GSM1153444
DR   GEO; GSM1177874
DR   GEO; GSM1177875
DR   GEO; GSM1177876
DR   GEO; GSM1181296
DR   GEO; GSM1181322
DR   GEO; GSM1669572
DR   GEO; GSM2124635
DR   IARC_TP53; 18076
DR   IARC_TP53; 28222
DR   IZSLER; BS TCL 124
DR   KCB; KCB 200941YJ
DR   LiGeA; CCLE_806
DR   LINCS_LDP; LCL-1773
DR   Lonza; 1087
DR   MetaboLights; MTBLS737
DR   NCI-DTP; 786-0
DR   PharmacoDB; 7860_28_2019
DR   PRIDE; PXD000335
DR   PRIDE; PXD000589
DR   PRIDE; PXD001493
DR   PRIDE; PXD003105
DR   PRIDE; PXD005453
DR   PRIDE; PXD005942
DR   SKY/M-FISH/CGH; 2782
DR   Wikidata; Q54604950
RX   PubMed=721102;
RX   PubMed=1010528;
RX   PubMed=2041050;
RX   PubMed=6244232;
RX   PubMed=7915601;
RX   PubMed=10700174;
RX   PubMed=15748285;
RX   PubMed=17088437;
RX   PubMed=19372543;
RX   PubMed=20164919;
RX   PubMed=22068913;
RX   PubMed=22384151;
RX   PubMed=22460905;
RX   PubMed=22628656;
RX   PubMed=22949125;
RX   PubMed=23856246;
RX   PubMed=23933261;
RX   PubMed=24279929;
RX   PubMed=24670534;
RX   PubMed=25485619;
RX   PubMed=25894527;
RX   PubMed=25984343;
RX   PubMed=26972028;
RX   PubMed=27141528;
RX   PubMed=27377824;
RX   PubMed=27397505;
RX   PubMed=27807467;
RX   PubMed=27993170;
RX   PubMed=28196595;
RX   PubMed=28489074;
RX   PubMed=30260228;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31267758;
RX   PubMed=31978347;
WW   https://dtp.cancer.gov/discovery_development/nci-60/cell_list.htm
WW   https://strap.nci.nih.gov/celline_detail.php?sample_id=40
WW   http://genome.ucsc.edu/ENCODE/protocols/cell/human/RCC7860_Crawford_protocol.pdf
WW   http://tcpaportal.org/mclp/
WW   http://www.cellresource.cn/fdetail.aspx?id=243
WW   http://www.cellresource.cn/fdetail.aspx?id=574
WW   http://www.cellresource.cn/fdetail.aspx?id=1696
WW   http://www.cellresource.cn/fdetail.aspx?id=2169
WW   http://www.cellresource.cn/fdetail.aspx?id=3296
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Part of: ENCODE project common cell types; tier 3.
CC   Part of: MD Anderson Cell Lines Project.
CC   Part of: NCI-60 cancer cell line panel.
CC   Doubling time: 45 hours (PubMed=721102); 24 hours (PubMed=25984343); ~24 hours (CLS); 22.4 hours (NCI-DTP).
CC   HLA typing: A*03:01:01; B*07,44; C*05,07:02:01; DPB1*04:02; DQB1*06,06; DRB1*13,15 (PubMed=15748285).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Homozygous for PTEN p.Gln149Ter (c.445C>T) (PubMed=17088437; CCLE; Cosmic-CLP).
CC   Sequence variation: TERT c.228C>T (-124C>T); in promoter (PubMed=31068700).
CC   Sequence variation: Heterozygous for TP53 c.560-2A>G; splice acceptor mutation and p.Pro278Ala (c.832C>G) (ClinVar=VCV000376645) (CCLE; Cosmic-CLP).
CC   Sequence variation: Homozygous for VHL p.Gly104fs*55 (c.311delG) (PubMed=17088437; CCLE; Cosmic-CLP).
CC   Omics: Array-based CGH.
CC   Omics: Cell surface proteome.
CC   Omics: CNV analysis.
CC   Omics: Deep exome analysis.
CC   Omics: Deep proteome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Fluorescence phenotype profiling.
CC   Omics: GPI-anchored proteins analysis by proteomics.
CC   Omics: lncRNA expression profiling.
CC   Omics: Metabolome analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: shRNA library screening.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=0.77%; Native American=0%; East Asian, North=4.36%; East Asian, South=0%; South Asian=0%; European, North=65.75%; European, South=29.12% (PubMed=30894373).
CC   Misspelling: 768-0; Occasionally.
CC   Misspelling: 796-0; Occasionally.
ST   Source(s): ATCC; CCRID; CLS; Cosmic-CLP; PubMed=19372543; PubMed=25877200
ST   Amelogenin: X,Y
ST   CSF1PO: 10
ST   D13S317: 8
ST   D16S539: 12
ST   D18S51: 13,14
ST   D19S433: 14,15
ST   D21S11: 29,30
ST   D2S1338: 17,18
ST   D3S1358: 16
ST   D5S818: 9
ST   D7S820: 11,12
ST   D8S1179: 13
ST   FGA: 24 (CCRID; PubMed=19372543; PubMed=25877200)
ST   FGA: 24,25 (CLS)
ST   Penta D: 9,12
ST   Penta E: 7,16
ST   TH01: 6,9.3
ST   TPOX: 8,11
ST   vWA: 15,17
DI   NCIt; C9385; Renal cell carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Male
AG   58Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-07-20; Version: 33
//
RX   PubMed=721102; DOI=10.1007/BF02617972;
RA   Williams R.D., Elliott A.Y., Stein N., Fraley E.E.;
RT   "In vitro cultivation of human renal cell cancer. II. Characterization
RT   of cell lines.";
RL   In Vitro 14:779-786(1978).
//
RX   PubMed=1010528; DOI=10.1007/BF02797460;
RA   Williams R.D., Elliott A.Y., Stein N., Fraley E.E.;
RT   "In vitro cultivation of human renal cell cancer. I. Establishment of
RT   cells in culture.";
RL   In Vitro 12:623-627(1976).
//
RX   PubMed=2041050; DOI=10.1093/jnci/83.11.757;
RA   Monks A., Scudiero D.A., Skehan P., Shoemaker R.H., Paull K.,
RA   Vistica D.T., Hose C., Langley J., Cronise P., Vaigro-Wolff A.,
RA   Gray-Goodrich M., Campbell H., Mayo J.G., Boyd M.R.;
RT   "Feasibility of a high-flux anticancer drug screen using a diverse
RT   panel of cultured human tumor cell lines.";
RL   J. Natl. Cancer Inst. 83:757-766(1991).
//
RX   PubMed=6244232;
RA   Williams R.D.;
RT   "Human urologic cancer cell lines.";
RL   Invest. Urol. 17:359-363(1980).
//
RX   PubMed=7915601; DOI=10.1038/ng0594-85;
RA   Gnarra J.R., Tory K., Weng Y., Schmidt L., Wei M.H., Li H., Latif F.,
RA   Liu S., Chen F., Duh F.-M., Lubensky I.A., Duan D.R., Florence C.,
RA   Pozzatti R., Walther M.M., Bander N.H., Grossman H.B., Brauch H.,
RA   Pomer S., Brooks J.D., Isaacs W.B., Lerman M.I., Zbar B.,
RA   Linehan W.M.;
RT   "Mutations of the VHL tumour suppressor gene in renal carcinoma.";
RL   Nat. Genet. 7:85-90(1994).
//
RX   PubMed=10700174; DOI=10.1038/73432;
RA   Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P.T.,
RA   Iyer V., Jeffrey S.S., van de Rijn M., Waltham M., Pergamenschikov A.,
RA   Lee J.C.F., Lashkari D., Shalon D., Myers T.G., Weinstein J.N.,
RA   Botstein D., Brown P.O.;
RT   "Systematic variation in gene expression patterns in human cancer cell
RT   lines.";
RL   Nat. Genet. 24:227-235(2000).
//
RX   PubMed=15748285; DOI=10.1186/1479-5876-3-11;
RA   Adams S., Robbins F.-M., Chen D., Wagage D., Holbeck S.L.,
RA   Morse H.C. III, Stroncek D., Marincola F.M.;
RT   "HLA class I and II genotype of the NCI-60 cell lines.";
RL   J. Transl. Med. 3:11-11(2005).
//
RX   PubMed=17088437; DOI=10.1158/1535-7163.MCT-06-0433;
RA   Ikediobi O.N., Davies H., Bignell G.R., Edkins S., Stevens C.,
RA   O'Meara S., Santarius T., Avis T., Barthorpe S., Brackenbury L.,
RA   Buck G., Butler A., Clements J., Cole J., Dicks E., Forbes S.,
RA   Gray K., Halliday K., Harrison R., Hills K., Hinton J., Hunter C.,
RA   Jenkinson A., Jones D., Kosmidou V., Lugg R., Menzies A.,
RA   Mironenko T., Parker A., Perry J., Raine K., Richardson D.,
RA   Shepherd R., Small A., Smith R., Solomon H., Stephens P., Teague J.W.,
RA   Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.;
RT   "Mutation analysis of 24 known cancer genes in the NCI-60 cell line
RT   set.";
RL   Mol. Cancer Ther. 5:2606-2612(2006).
//
RX   PubMed=19372543; DOI=10.1158/1535-7163.MCT-08-0921;
RA   Lorenzi P.L., Reinhold W.C., Varma S., Hutchinson A.A., Pommier Y.,
RA   Chanock S.J., Weinstein J.N.;
RT   "DNA fingerprinting of the NCI-60 cell line panel.";
RL   Mol. Cancer Ther. 8:713-724(2009).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=22068913; DOI=10.1073/pnas.1111840108;
RA   Gillet J.-P., Calcagno A.M., Varma S., Marino M., Green L.J.,
RA   Vora M.I., Patel C., Orina J.N., Eliseeva T.A., Singal V.,
RA   Padmanabhan R., Davidson B., Ganapathi R., Sood A.K., Rueda B.R.,
RA   Ambudkar S.V., Gottesman M.M.;
RT   "Redefining the relevance of established cancer cell lines to the
RT   study of mechanisms of clinical anti-cancer drug resistance.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:18708-18713(2011).
//
RX   PubMed=22384151; DOI=10.1371/journal.pone.0032096;
RA   Lee J.-S., Kim Y.K., Kim H.J., Hajar S., Tan Y.L., Kang N.-Y., Ng S.H.,
RA   Yoon C.N., Chang Y.-T.;
RT   "Identification of cancer cell-line origins using fluorescence
RT   image-based phenomic screening.";
RL   PLoS ONE 7:E32096-E32096(2012).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=22628656; DOI=10.1126/science.1218595;
RA   Jain M., Nilsson R., Sharma S., Madhusudhan N., Kitami T., Souza A.L.,
RA   Kafri R., Kirschner M.W., Clish C.B., Mootha V.K.;
RT   "Metabolite profiling identifies a key role for glycine in rapid
RT   cancer cell proliferation.";
RL   Science 336:1040-1044(2012).
//
RX   PubMed=22949125; DOI=10.1002/ijc.27822;
RA   Pawlowski R., Muhl S.M., Sulser T., Krek W., Moch H., Schraml P.;
RT   "Loss of PBRM1 expression is associated with renal cell carcinoma
RT   progression.";
RL   Int. J. Cancer 132:E11-E17(2013).
//
RX   PubMed=23856246; DOI=10.1158/0008-5472.CAN-12-3342;
RA   Abaan O.D., Polley E.C., Davis S.R., Zhu Y.J., Bilke S., Walker R.L.,
RA   Pineda M., Gindin Y., Jiang Y., Reinhold W.C., Holbeck S.L.,
RA   Simon R.M., Doroshow J.H., Pommier Y., Meltzer P.S.;
RT   "The exomes of the NCI-60 panel: a genomic resource for cancer biology
RT   and systems pharmacology.";
RL   Cancer Res. 73:4372-4382(2013).
//
RX   PubMed=23933261; DOI=10.1016/j.celrep.2013.07.018;
RA   Moghaddas Gholami A., Hahne H., Wu Z., Auer F.J., Meng C., Wilhelm M.,
RA   Kuster B.;
RT   "Global proteome analysis of the NCI-60 cell line panel.";
RL   Cell Rep. 4:609-620(2013).
//
RX   PubMed=24279929; DOI=10.1186/2049-3002-1-20;
RA   Dolfi S.C., Chan L.L.-Y., Qiu J., Tedeschi P.M., Bertino J.R.,
RA   Hirshfield K.M., Oltvai Z.N., Vazquez A.;
RT   "The metabolic demands of cancer cells are coupled to their size and
RT   protein synthesis rates.";
RL   Cancer Metab. 1:20-20(2013).
//
RX   PubMed=24670534; DOI=10.1371/journal.pone.0092047;
RA   Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C.;
RT   "High resolution copy number variation data in the NCI-60 cancer cell
RT   lines from whole genome microarrays accessible through CellMiner.";
RL   PLoS ONE 9:E92047-E92047(2014).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H.,
RA   Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y.,
RA   Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D.,
RA   Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D.,
RA   Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S.,
RA   Zhang Z.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25894527; DOI=10.1371/journal.pone.0121314;
RA   Bausch-Fluck D., Hofmann A., Bock T., Frei A.P., Cerciello F.,
RA   Jacobs A., Moest H., Omasits U., Gundry R.L., Yoon C., Schiess R.,
RA   Schmidt A., Mirkowska P., Hartlova A., Van Eyk J.E., Bourquin J.-P.,
RA   Aebersold R., Boheler K.R., Zandstra P., Wollscheid B.;
RT   "A mass spectrometric-derived cell surface protein atlas.";
RL   PLoS ONE 10:E0121314-E0121314(2015).
//
RX   PubMed=25984343; DOI=10.1038/sdata.2014.35;
RA   Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S.,
RA   East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H.,
RA   Jiang G., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M.,
RA   Harrington W., Gelfand E., Green T.M., Tomko M.J., Gopal S.,
RA   Wong T.C., Li H., Howell S., Stransky N., Liefeld T., Jang D.,
RA   Bistline J., Hill Meyers B., Armstrong S.A., Anderson K.C.,
RA   Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P.,
RA   Golub T.R., Root D.E., Hahn W.C.;
RT   "Parallel genome-scale loss of function screens in 216 cancer cell
RT   lines for the identification of context-specific genetic
RT   dependencies.";
RL   Sci. Data 1:140035-140035(2014).
//
RX   PubMed=26972028; DOI=10.1016/j.jprot.2016.03.008;
RA   Masuishi Y., Kimura Y., Arakawa N., Hirano H.;
RT   "Identification of glycosylphosphatidylinositol-anchored proteins and
RT   omega-sites using TiO2-based affinity purification followed by
RT   hydrogen fluoride treatment.";
RL   J. Proteomics 139:77-83(2016).
//
RX   PubMed=27141528; DOI=10.1016/j.dib.2016.04.001;
RA   Masuishi Y., Kimura Y., Arakawa N., Hirano H.;
RT   "Data for identification of GPI-anchored peptides and omega-sites in
RT   cancer cell lines.";
RL   Data Brief 7:1302-1305(2016).
//
RX   PubMed=27377824; DOI=10.1038/sdata.2016.52;
RA   Mestdagh P., Lefever S., Volders P.-J., Derveaux S., Hellemans J.,
RA   Vandesompele J.;
RT   "Long non-coding RNA expression profiling in the NCI60 cancer cell
RT   line panel using high-throughput RT-qPCR.";
RL   Sci. Data 3:160052-160052(2016).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=27807467; DOI=10.1186/s13100-016-0078-4;
RA   Zampella J.G., Rodic N., Yang W.R., Huang C.R.L., Welch J.,
RA   Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H.;
RT   "A map of mobile DNA insertions in the NCI-60 human cancer cell
RT   panel.";
RL   Mob. DNA 7:20-20(2016).
//
RX   PubMed=27993170; DOI=10.1186/s12943-016-0565-8;
RA   Brodaczewska K.K., Szczylik C., Fiedorowicz M., Porta C.,
RA   Czarnecka A.M.;
RT   "Choosing the right cell line for renal cell cancer research.";
RL   Mol. Cancer 15:83-83(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P.,
RA   Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=28489074; DOI=10.1038/ncomms15165;
RA   Sinha R., Winer A.G., Chevinsky M., Jakubowski C., Chen Y.-B., Dong Y.,
RA   Tickoo S.K., Reuter V.E., Russo P., Coleman J.A., Sander C.,
RA   Hsieh J.J., Hakimi A.A.;
RT   "Analysis of renal cancer cell lines from two major resources enables
RT   genomics-guided cell line selection.";
RL   Nat. Commun. 8:15165-15165(2017).
//
RX   PubMed=30260228; DOI=10.1021/acs.jproteome.8b00538;
RA   Knott M.E., Manzi M., Zabalegui N., Salazar M.O., Puricelli L.I.,
RA   Monge M.E.;
RT   "Metabolic footprinting of a clear cell renal cell carcinoma in vitro
RT   model for human kidney cancer detection.";
RL   J. Proteome Res. 17:3877-3888(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31267758; DOI=10.2217/fon-2019-0067;
RA   Nogueira I., Dias F., Morais M., Teixeira A.L., Medeiros R.;
RT   "Everolimus resistance in clear cell renal cell carcinoma: miRNA-101
RT   and HIF-2alpha as molecular triggers?";
RL   Future Oncol. 15:2361-2370(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E., Schweppe D.K.,
RA   Jedrychowski M., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//